Search Results 101-110 of 8390 for TNF

1. A Study to Evaluate the Safety and Effectiveness of Ustekinumab Induction and Maintenance Therapy in Participants with Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

   OR has not had biologic therapy (TNF antagonists or vedolizumab); Has received biologic therapy but has not demonstrated a history of failure to respond to ...

2. A Study to Evaluate the Safety and Effectiveness of BMS-986165 in Subjects with Moderate-to-Severe Ulcerative Colitis (UC) - Mayo Clinic

   ... tumor necrosis factor (TNF)-α agents, integrin inhibitor. Exclusion Criteria: Participant with current diagnosis of Crohn's disease (CD) or diagnosis of ...

3. Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL - Mayo Clinic

   Being treated with anti-TNF therapies or has been treated with an anti-TNF therapy within 5 half-lives of randomization. Participating Mayo Clinic locations.

4. A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302) - Mayo Clinic

   ... TNF. Subjects receiving any treatment(s) for UC are eligible provided they have been, and are anticipated to be, on a stable dose for the designated period ...

5. A Study of the Effect of Vedolizumab in Conjunction with Structured Semi-Vegetarian Diet on the Treatment of Ulcerative Colitis - Mayo Clinic

   Patients who were previously exposed to tumor necrosis factor (TNF) ... TNF antagonists, a documentation of unsuccessful previous treatment (i.e. ...

6. Publications - Konstantinos A. Papadakis, M.D. - Mayo Clinic

   Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns ...

7. Publications - Sunanda V. Kane, M.D. - Mayo Clinic

   ... Tumor Necrosis Factor Therapy. Dig Dis Sci. 2023 Sep; 68 (9):3557-3561 ... Safety of anti-TNF agents in pregnancy. J Allergy Clin Immunol. 2021 Sep ...

8. A Study of the Effectiveness of Methotrexate as Initial Treatment and Maintenance of a Steroid Free Remission in Ulcerative Colitis - Mayo Clinic

   Primary failure or loss of response to an anti-TNF (infliximab, adalimumab, golimumab) in the past; Primary failure or loss of response to vedolizumab in the ...

9. Curriculum - Summer Undergraduate Research Fellowship (SURF) - Mayo Clinic College of Medicine & Science

   The Sensitizing Effects of TRAF2 Deficiency on TNF- and IFNy-Induced Cancer Cell Death; Utilizing Molecular Dynamics Simulations to Characterize Pathogenic ...

10. Rilonacept in Subjects with Cardiac Sarcoidosis - Mayo Clinic

    Planned to initiate TNF-α antagonist therapy over the course of the study. ... TNF inhibitors within 2-8 weeks of or 5 half-lives (etanercept within 2 ...